Botulinum Toxin in Overactive Bladder

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 240-256

  Schurch, Brigitte ^a   Dykstra, Dennis ^b  

^a SWISS PARAPLEGIC RESEARCH   (Switzerland)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951002062     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00020-2     Document Type: Chapter

References (87)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167-178.
2. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999, 161:1809-1812.
3. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414-421.
4. Wojdan A, Freeden C, Woods M, Oshiro G, Spinelli W, Colatsky TJ, et al. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J Pharmacol Exp Ther 1999, 289:1410-1418.
5. Igawa Y, Yamazaki Y, Takeda H, Kaidoh K, Akahane M, Ajisawa Y, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol 2001, 165:240-244.
6. Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol 1997, 120:231-238.
7. Kamo I, Imai S, Okanishi S, Doi T Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol 2000, 401:235-240.
8. Enzelsberger H, Helmer H, Kurz C Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 1995, 102:929-930.
9. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005, 23:263-270.
10. Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992, 339:1239.
11. Cruz F, Guimaraes M, Silva C, Reis M Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997, 350:640-641.
12. Kerner J Das Fettgift oder die Fettsäure und ihre Wirkungen auf den tierischen Orgismus; ein Beytrag zur Untersuchung des in Verdorbenen Würsten giftig wirkenden Stoffes 1822, Cotta, Stuttgart.
13. Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003, 169:1896-1900.
14. MacKenzie I, Burnstock G, Dolly JO The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982, 7:997-1006.
15. Durham PL, Cady R Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35-42. discussion 43.
16. Rapp DE, Turk KW, Bales GT, Cook SP Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006, 175(3 Pt 1):1138-1142.
17. Cui M, Khanijou S, Rubino J, Aoki KR Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107(1-2):125-133.
18. Lucioni A, Bales GT, Turk KW, Lotan T, Cook SP, Rapp DE Botulinum toxin type A inhibits substance P release in inflammatory rat bladder model. J Urol 2006, 175(4 suppl):91-93.
19. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005, 174:977-982. discussion 82-83.
20. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006, 50:1058-1064.
21. Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006, 175:2341-2344.
22. Kuo HC Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005, 66:94-98.
23. Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007, 177:1011-1014.
24. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65:37-41.
25. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164(3 Pt 1):692-697.
26. Karsenty G, Carsenac A, Boy S, Reitz A, Tournebise H, Bladou F, et al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrudor overcativity (NDOI)-A prospective randomized study to compare 30 vs. 10 injection sites. Eur Urol 2007, 2:245.
27. Boy S, Schmid M, Reitz A, Von Hessling A, Hodler J, Schurch B Botulinum toxin injections into the bladder wall-A morphological evaluation of the injection technique using magnetic resonance imaging. J Urol 2006, 175(4 suppl):415.
28. Abrams P, Freeman R, Anderstrom C, Mattiasson A Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998, 81:801-810.
29. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999, 10:283-289.
30. Appell RA Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50(6A suppl):90-96. discussion 7-9.
31. Kreder K, Mayne C, Jonas U Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002, 41:588-595.
32. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174:196-200.
33. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004, 45:510-515.
34. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004, 172:240-243.
35. Patki P, Hamid R, Arumugam K, Shah J, Craggs M Botulinum-A txoin (Dysport) in the treatment of drug resistant neurogenic detrusor overactivity following traumatic spinal cord injury. BJU Int 2006, 98:77-82.
36. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007, 41:335-340.
37. Del Popolo G, Li Marzi V, Panariello G, Lombardi G English Botulinum toxin-A in the treatment of neurogenic detruos overactivity. Neurourol Urodyn 2003, 22:498.
38. Giannantoni A, Merini E, Di Stasi SM, Constantini E, Zuchhi A, Mearini L, et al. New therapeutic option for refractory neurogenic detrusor overactivity. Minerva Urol Nephrol 2004, 56:78-87.
39. Kennely M, Kang J Botulinum-A toxin injection into the detrusor as treatment for refractory detrusor hyperreflexia. Top Spinal Cord Inj Rehabil 2003, 8:46-53.
40. Kuo HC Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004, 63:868-872.
41. Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 2005, 12:2543-2546.
42. Klaphajone J, Kitisomprayoonkul W, Sriplakit S Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 2005, 86:2114-2118.
43. Hernandez RD, Hurwitz RS, Foote JE, Zimmern PE, Leach GE Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 1994, 152(5 Pt 1):1582-1585.
44. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002, 59:325-327. discussion 7-8.
45. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003, 44:139-143.
46. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004, 171(2 Pt 1):845-848. discussion 8.
47. Corcos J, Al-Taweed W, Robichaud C Botulinum toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomeningocele [abstract]. J Urol 2004, 171:181.
48. Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005, 66:865-870. discussion 70.
49. Werner M, Schmid DM, Schussler B Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005, 192:1735-1740.
50. Schulte-Baukloh H, Weiss C, Schobert J, Stolze T, Sturzebecher B, Knispel HH [Subjective patient satisfaction after injection of botulinum-A toxin in detrusor overactivity]. Aktuelle Urol 2005, 36:230-233.
51. Sahai A, Khan M, Smith K, Dasgupta P Botulinum toxin for patients with detrusor overactivity: Early results from a randomised, double blind placebo-controlled trial. International Continence Society Annual Meeting, Montreal 2005, Abstract 468(5).
52. Rajkumar GN, Small DR, Mustafa AW, Conn G A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005, 96:848-852.
53. Dykstra D, Enriquez A, Valley M Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003, 14:424-426.
54. Loch A, Loch T, Osterhage J, Alloussi S, Stöckle M Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence [abstract]. Eur Urol 2003, 2:172.
55. Radziszewski P, Borkowski A Botulinum toxin type A intravesical injections for instable bladder overactivity. Eur Urol 2002, 1:134.
56. Flynn MK, Webster GD, Amundsen CL The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004, 172(6 Pt 1):2316-2320.
57. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005, 174:984-989.
58. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 2005, 24:231-236.
59. Schmid DM, Schurch B, John H, Hauri D Botulinum toxin injection to treat overactive bladder. Eur Urol 2004, (Suppl 3):131.
60. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience of 100 cases treated with botulinum-A toxin injections into the detrusor muscle for idiopathic overactive bladder refractory to anticholinergics. J Urol 2006, 176:177-185.
61. Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive bladder. J Urol 2006, 176:328-330.
62. Kuo HC Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. Urology 2006, 68:993-997. discussion 7-8.
63. Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Sturzebecher B, Miller K, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005, 48:984-990. discussion 90.
64. Dykstra DD, Pryor J, Goldish G Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil 2003, 84:1399-1400.
65. Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005, 174:1873-1877. discussion 7.
66. Reitz A, Schurch B Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004, 171(2 Pt 1):804-805. discussion.
67. Pistolesi D, Selli C, Rossi B, Stampacchia G Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004, 171(2 Pt 1):802-803.
68. Kessler KR, Benecke R The EBD test-a clinical test for the detection of antibodies to botulinum type A. Mov Disord 1997, 12:95-99.
69. Aoki KR Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001, 248(Suppl 1):3-10.
70. Matarasso SL Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003, 29:7-13. discussion.
71. Alderson K, Holds JB, Anderson RL Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991, 41:1800-1805.
72. Printer MJ, Vanden Noven S, Muccio D, Wallace N Axotomy-like changes in cat motor neuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission. J Neurosci 1991, 11:657-666.
73. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999, 96:3200-3205.
74. Grosse J, Kramer G, Schurch B, Stöhrer M Repeat injections of botulinum-A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolearnce. Neurourol Urodyn 2002, 21:287-386.
75. Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004, 46:784-791.
76. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B Persistence of therapeutic effect after repeated injections of botulinum A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006, 68:1193-1197.
77. Grosse J, Kramer G, Stohrer M Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005, 47:653-659.
78. Malnick SD, Metchnik L, Somin M, Bergman N, Attali M Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol 2000, 95:3333-3334.
79. Del Popolo G Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn 2001, 20:522.
80. Wyndaele JJ, Van Dromme SA Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002, 40:599-600.
81. Dykstra DD, Sidi AA Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990, 71:24-26.
82. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002, 72:459-462.
83. Van den, Bergh PY, Lison DF Dose standardization of botulinum toxin. Adv Neurol 1998, 78:231-235.
84. Leippold T, Reitz A, Schurch B Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003, 44:165-174.
85. Schurch B, Corcos J Botulinum toxin injections for paediatric incontinence. Curr Opin Urol 2005, 15:264-267.
86. Kalsi V, Popat R, Odyemi I, Borrill J, Fowler CJ, Dasgupta P A cost effectiveness model for botulinum neurotoxin type A (BoNT/A) in the treatment of patients with detrusor overactivity: preliminary results. BJU Int 2005, 95(Supplement 5):60-61.
87. Bagi P, Bierig Soerensen F Botulinum A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesion. Scand J Urol Nephrol 2004, 38:495-498.